TOP TIERMARKET NEWSWIRE
Movers explained · September 23, 2026

Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Down Today?

By the Top Tier Newswire AI Desk · reviewed against 4 wire stories

RAPPORT THERAPEUTICS Equity (RAPP) is down -13.54% in the latest session. Our newswire has captured 4 stories on RAPP across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

The written analysis for RAPP publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.

RAPP by the numbers

Last: $35.86Session: -13.54%Coverage: 4 stories / 2 sourcesAI sentiment: 57/100 (mixed)
RAPP · today's session (5-min) · -12.23% vs prior close · updated 11:07 AM ET
$35.98$38.88$41.78prev close $41.47$36.409:30 AM9:53 AM10:17 AM10:41 AM11:05 AM9:30 AM · $41.059:35 AM · $40.459:40 AM · $39.989:45 AM · $39.749:50 AM · $39.459:55 AM · $39.4010:00 AM · $38.8510:05 AM · $38.4710:10 AM · $38.2710:15 AM · $38.5110:20 AM · $38.2710:25 AM · $37.9610:30 AM · $37.6010:35 AM · $37.5810:40 AM · $37.5310:45 AM · $36.9710:50 AM · $36.7510:55 AM · $36.4411:00 AM · $36.2911:05 AM · $36.40
AI sentiment, last 36h · averaged over 4 stories · 57/100 bullish
AI sentiment 57/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowInvesting.com Analyst Ratings · sentiment 61 · Raymond James reiterates Strong Buy on Rapport Therapeutics stockInvesting.com Analyst Ratings · 61Raymond James reiterates Strong Buy on Rapport Therapeutics stockSeeking Alpha · sentiment 56 · Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania TranscriptSeeking Alpha · 56Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bip…Investing.com Analyst Ratings · sentiment 56 · Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potentialInvesting.com Analyst Ratings · 56Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potentialSeeking Alpha · sentiment 54 · Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant SuccessSeeking Alpha · 54Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success
1h agoSeeking AlphaNEUTRAL 54Analyst

Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success

Rapport Therapeutics' current valuation reflects substantial optimism ahead of pivotal bipolar mania data for RAP-219. See why I rate RAPP stock a Hold.

5h agoInvesting.com Analyst RatingsBULLISH 56Analyst

Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potential

Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potential

14h agoSeeking AlphaBULLISH 56Product/PR

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania September 22, 2026 12:30 PM EDTCompany...

18h agoInvesting.com Analyst RatingsBULLISH 61Analyst

Raymond James reiterates Strong Buy on Rapport Therapeutics stock

Raymond James reiterates Strong Buy on Rapport Therapeutics stock

Frequently asked questions

Why is RAPP stock down today?

RAPPORT THERAPEUTICS Equity (RAPP) is down -13.54% in the latest session. Our newswire has captured 4 stories on RAPP across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100). The most recent driver: "Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success" (Seeking Alpha).

Is RAPP a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RAPP coverage reads 57/100 over 4 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on RAPP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.